ClinicoEconomics and Outcomes Research
Volume 16, 2024 - Issue
PERSPECTIVES
Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review
Grace E Fox1 Strategic Market Access, OPEN Health, Bethesda, MD, USA
https://orcid.org/0009-0001-2181-3145View further author information
https://orcid.org/0009-0001-2181-3145View further author information, Mark Bernauer1 Strategic Market Access, OPEN Health, Bethesda, MD, USACorrespondence[email protected]
https://orcid.org/0000-0002-4894-6650View further author information
https://orcid.org/0000-0002-4894-6650View further author information, Jennifer M Stephens1 Strategic Market Access, OPEN Health, Bethesda, MD, USAhttps://orcid.org/0000-0002-5623-7934View further author information
https://orcid.org/0000-0002-5623-7934View further author information, Bianca Jackson1 Strategic Market Access, OPEN Health, Bethesda, MD, USAhttps://orcid.org/0009-0001-2367-816XView further author information
https://orcid.org/0009-0001-2367-816XView further author information, Joshua A Roth2 Global Access and Value, Pfizer Inc., New York, NY, USAhttps://orcid.org/0000-0001-6621-8342View further author information
https://orcid.org/0000-0001-6621-8342View further author information & Ahmed Shelbaya2 Global Access and Value, Pfizer Inc., New York, NY, USA;3 Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USAhttps://orcid.org/0000-0003-1028-5866View further author information
https://orcid.org/0000-0003-1028-5866View further author information